• Bivalirudin may reduce risk for 30-day mortality after PCI in STEMI

    1 day ago - By Healio

    Compared with heparin, bivalirudin reduced the risk for 30-day mortality, serious bleeding and net adverse clinical events in patients with STEMI undergoing PCI despite increased rates of stent thrombosis and MI, researchers found.
    “The mortality benefit of bivalirudin in STEMI patients was pronounced in those treated with a post-PCI bivalirudin infusion, either low dose or high dose, although the high-dose infusion mitigated the MI and stent thrombosis risk,” Gregg W. Stone, MD, director of academic affairs for the Mount Sinai Heart Health System, professor of medicine
    Read more ...